| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diarrhea | 57 | 2022 | 686 | 6.940 |
Why?
|
| Escherichia coli Infections | 24 | 2021 | 241 | 5.110 |
Why?
|
| Travel | 37 | 2014 | 190 | 4.500 |
Why?
|
| Cryptosporidiosis | 33 | 2022 | 86 | 4.100 |
Why?
|
| Cryptosporidium parvum | 23 | 2022 | 60 | 2.570 |
Why?
|
| Escherichia coli | 17 | 2020 | 1203 | 2.240 |
Why?
|
| Feces | 29 | 2021 | 770 | 1.930 |
Why?
|
| Cryptosporidium | 14 | 2022 | 47 | 1.850 |
Why?
|
| Bacterial Toxins | 5 | 2021 | 228 | 1.410 |
Why?
|
| Enterotoxigenic Escherichia coli | 6 | 2019 | 12 | 1.140 |
Why?
|
| Escherichia coli Proteins | 9 | 2020 | 359 | 1.140 |
Why?
|
| Mexico | 25 | 2014 | 259 | 1.050 |
Why?
|
| Enteropathogenic Escherichia coli | 2 | 2021 | 10 | 0.830 |
Why?
|
| Norovirus | 6 | 2016 | 287 | 0.800 |
Why?
|
| Clostridium Infections | 3 | 2021 | 252 | 0.780 |
Why?
|
| Encephalitis, Viral | 1 | 2021 | 30 | 0.770 |
Why?
|
| Enterotoxins | 4 | 2008 | 112 | 0.770 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 39 | 0.760 |
Why?
|
| Virulence Factors | 6 | 2020 | 213 | 0.750 |
Why?
|
| Rifamycins | 7 | 2011 | 32 | 0.740 |
Why?
|
| Herpesvirus 6, Human | 1 | 2021 | 81 | 0.730 |
Why?
|
| Neoplasms | 11 | 2022 | 15193 | 0.730 |
Why?
|
| Molecular Epidemiology | 5 | 2017 | 246 | 0.700 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 698 | 0.700 |
Why?
|
| Antibodies, Protozoan | 10 | 2005 | 87 | 0.650 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2021 | 163 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2011 | 4549 | 0.620 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2023 | 907 | 0.600 |
Why?
|
| Polymerase Chain Reaction | 12 | 2019 | 3203 | 0.600 |
Why?
|
| Virulence | 10 | 2010 | 323 | 0.590 |
Why?
|
| Bacteriological Techniques | 2 | 2015 | 121 | 0.580 |
Why?
|
| Interferon-gamma | 6 | 2010 | 1144 | 0.550 |
Why?
|
| Protozoan Proteins | 4 | 2005 | 114 | 0.550 |
Why?
|
| Hydroxylamine | 1 | 2015 | 3 | 0.550 |
Why?
|
| Environmental Microbiology | 1 | 2015 | 22 | 0.540 |
Why?
|
| Bacterial Adhesion | 6 | 2020 | 147 | 0.510 |
Why?
|
| Interleukin-8 | 7 | 2007 | 519 | 0.490 |
Why?
|
| Virus Diseases | 2 | 2021 | 398 | 0.470 |
Why?
|
| Rotavirus | 1 | 2016 | 377 | 0.460 |
Why?
|
| Disease Outbreaks | 4 | 2014 | 415 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 11 | 2021 | 2992 | 0.460 |
Why?
|
| Adult | 64 | 2021 | 77950 | 0.450 |
Why?
|
| Indoles | 2 | 2016 | 1009 | 0.450 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2010 | 69 | 0.430 |
Why?
|
| Humans | 118 | 2023 | 261506 | 0.430 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2006 | 362 | 0.410 |
Why?
|
| Enterobacteriaceae | 2 | 2009 | 46 | 0.410 |
Why?
|
| Lactoferrin | 3 | 2007 | 81 | 0.410 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 86 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2011 | 1489 | 0.390 |
Why?
|
| Adenoviridae | 1 | 2016 | 1459 | 0.380 |
Why?
|
| Aminopeptidases | 4 | 2002 | 34 | 0.380 |
Why?
|
| Gastrointestinal Diseases | 4 | 2021 | 589 | 0.380 |
Why?
|
| Anti-Infective Agents | 5 | 2013 | 446 | 0.370 |
Why?
|
| Antibodies, Bacterial | 3 | 2010 | 380 | 0.370 |
Why?
|
| Caliciviridae Infections | 5 | 2010 | 279 | 0.370 |
Why?
|
| Cholera Toxin | 1 | 2010 | 63 | 0.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2002 | 317 | 0.360 |
Why?
|
| Blood | 1 | 2010 | 156 | 0.350 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 24 | 0.340 |
Why?
|
| Intestinal Mucosa | 7 | 2020 | 1081 | 0.340 |
Why?
|
| Jejunum | 6 | 2003 | 216 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 4 | 2011 | 3101 | 0.330 |
Why?
|
| Immunoglobulin G | 10 | 2014 | 1021 | 0.330 |
Why?
|
| Occult Blood | 1 | 2008 | 64 | 0.320 |
Why?
|
| Developing Countries | 2 | 2007 | 315 | 0.310 |
Why?
|
| Intestinal Diseases | 1 | 2009 | 121 | 0.310 |
Why?
|
| United States | 21 | 2016 | 15433 | 0.300 |
Why?
|
| Acid Phosphatase | 1 | 2007 | 59 | 0.300 |
Why?
|
| Colitis | 2 | 2021 | 340 | 0.300 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2014 | 208 | 0.300 |
Why?
|
| Biofilms | 3 | 2013 | 199 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 1833 | 0.290 |
Why?
|
| Loperamide | 3 | 2007 | 14 | 0.290 |
Why?
|
| Disease Susceptibility | 7 | 2016 | 538 | 0.290 |
Why?
|
| Antiparasitic Agents | 2 | 2006 | 39 | 0.280 |
Why?
|
| HIV-1 | 3 | 2011 | 653 | 0.280 |
Why?
|
| HIV Enteropathy | 2 | 2002 | 3 | 0.280 |
Why?
|
| Animals | 45 | 2022 | 59536 | 0.270 |
Why?
|
| Ofloxacin | 1 | 2005 | 41 | 0.270 |
Why?
|
| Immunity, Innate | 1 | 2010 | 677 | 0.270 |
Why?
|
| Levofloxacin | 1 | 2005 | 57 | 0.270 |
Why?
|
| Interleukin-10 | 1 | 2008 | 478 | 0.260 |
Why?
|
| Ceftriaxone | 1 | 2005 | 67 | 0.260 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 89 | 0.260 |
Why?
|
| Male | 47 | 2021 | 123000 | 0.260 |
Why?
|
| DNA, Bacterial | 7 | 2010 | 558 | 0.260 |
Why?
|
| Female | 49 | 2023 | 141928 | 0.250 |
Why?
|
| Fluoroquinolones | 1 | 2005 | 126 | 0.250 |
Why?
|
| Students | 6 | 2011 | 324 | 0.250 |
Why?
|
| Adolescent | 20 | 2017 | 31252 | 0.250 |
Why?
|
| Seasons | 4 | 2016 | 340 | 0.240 |
Why?
|
| Interleukin-12 | 1 | 2005 | 253 | 0.240 |
Why?
|
| Hypoglycemia | 1 | 2005 | 213 | 0.240 |
Why?
|
| Prebiotics | 1 | 2023 | 34 | 0.230 |
Why?
|
| Immunoglobulin A | 4 | 2010 | 237 | 0.230 |
Why?
|
| Antidiarrheals | 3 | 2007 | 37 | 0.230 |
Why?
|
| Cohort Studies | 8 | 2022 | 9244 | 0.220 |
Why?
|
| Cytokines | 5 | 2021 | 2809 | 0.220 |
Why?
|
| Middle Aged | 33 | 2021 | 86204 | 0.220 |
Why?
|
| Hyperglycemia | 1 | 2005 | 333 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2009 | 5539 | 0.210 |
Why?
|
| Deer | 1 | 2002 | 11 | 0.210 |
Why?
|
| CD13 Antigens | 1 | 2002 | 36 | 0.210 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2002 | 82 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 657 | 0.200 |
Why?
|
| Protozoan Infections | 1 | 2001 | 16 | 0.200 |
Why?
|
| Inflammation | 5 | 2023 | 2522 | 0.200 |
Why?
|
| Eukaryota | 1 | 2001 | 27 | 0.200 |
Why?
|
| Cryptococcus | 1 | 2021 | 8 | 0.200 |
Why?
|
| Ribotyping | 1 | 2021 | 48 | 0.200 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2001 | 36 | 0.200 |
Why?
|
| Cryptococcosis | 1 | 2021 | 63 | 0.190 |
Why?
|
| Risk Assessment | 10 | 2019 | 6869 | 0.190 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2020 | 54 | 0.190 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Immunocompetence | 2 | 2014 | 75 | 0.180 |
Why?
|
| Enterococcus faecalis | 2 | 2004 | 49 | 0.180 |
Why?
|
| Gastroenteritis | 3 | 2014 | 300 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 4971 | 0.170 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1870 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 408 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 490 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2021 | 12873 | 0.170 |
Why?
|
| Canada | 2 | 2011 | 429 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 462 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2001 | 350 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2011 | 2803 | 0.160 |
Why?
|
| Colostrum | 1 | 1998 | 49 | 0.160 |
Why?
|
| Neutropenia | 1 | 2022 | 968 | 0.160 |
Why?
|
| Safety | 1 | 2020 | 465 | 0.160 |
Why?
|
| Viral Tropism | 1 | 2018 | 40 | 0.160 |
Why?
|
| Risk Factors | 11 | 2021 | 17523 | 0.160 |
Why?
|
| Gastrointestinal Agents | 2 | 2010 | 108 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2019 | 256 | 0.160 |
Why?
|
| Protease Inhibitors | 3 | 2002 | 210 | 0.160 |
Why?
|
| Retrospective Studies | 12 | 2022 | 37905 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 1998 | 172 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 78 | 0.150 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 354 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2019 | 209 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 598 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2019 | 2086 | 0.150 |
Why?
|
| Telomere | 1 | 2020 | 505 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 547 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2021 | 576 | 0.150 |
Why?
|
| Young Adult | 9 | 2017 | 21445 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 324 | 0.150 |
Why?
|
| Oocysts | 3 | 2011 | 8 | 0.140 |
Why?
|
| Incidence | 6 | 2019 | 5673 | 0.140 |
Why?
|
| Double-Blind Method | 9 | 2011 | 2588 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2010 | 181 | 0.140 |
Why?
|
| HIV Infections | 3 | 2011 | 2134 | 0.140 |
Why?
|
| Overweight | 1 | 2019 | 484 | 0.140 |
Why?
|
| Leucine | 3 | 2002 | 352 | 0.140 |
Why?
|
| Food Microbiology | 3 | 2010 | 26 | 0.130 |
Why?
|
| Tryptophan | 1 | 2015 | 127 | 0.130 |
Why?
|
| Chronic Disease | 4 | 2005 | 1819 | 0.130 |
Why?
|
| North America | 2 | 2007 | 314 | 0.130 |
Why?
|
| Virus Shedding | 1 | 1995 | 88 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 1073 | 0.130 |
Why?
|
| Peptides | 2 | 2001 | 1479 | 0.130 |
Why?
|
| Calmodulin | 1 | 1995 | 241 | 0.120 |
Why?
|
| Providencia | 1 | 2014 | 3 | 0.120 |
Why?
|
| Nitro Compounds | 2 | 2004 | 23 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 418 | 0.120 |
Why?
|
| Genes, Bacterial | 4 | 2008 | 236 | 0.120 |
Why?
|
| Norwalk virus | 1 | 1995 | 127 | 0.120 |
Why?
|
| Soft Tissue Injuries | 1 | 1994 | 51 | 0.120 |
Why?
|
| Piperacillin | 1 | 1993 | 29 | 0.120 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2013 | 158 | 0.120 |
Why?
|
| Penicillanic Acid | 1 | 1993 | 20 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 1439 | 0.120 |
Why?
|
| Penicillin Resistance | 1 | 1993 | 69 | 0.120 |
Why?
|
| Immunoglobulins | 2 | 2014 | 266 | 0.120 |
Why?
|
| Encephalitis, St. Louis | 1 | 1993 | 21 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2009 | 2307 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1217 | 0.120 |
Why?
|
| Soft Tissue Infections | 1 | 1994 | 102 | 0.110 |
Why?
|
| Intestines | 1 | 2018 | 686 | 0.110 |
Why?
|
| Aged | 12 | 2021 | 70117 | 0.110 |
Why?
|
| Antiprotozoal Agents | 2 | 2003 | 40 | 0.110 |
Why?
|
| Peptidomimetics | 1 | 2013 | 26 | 0.110 |
Why?
|
| Mucormycosis | 1 | 1994 | 108 | 0.110 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 1993 | 52 | 0.110 |
Why?
|
| Parasitic Diseases | 1 | 2013 | 65 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 1450 | 0.110 |
Why?
|
| Mucus | 2 | 2022 | 119 | 0.110 |
Why?
|
| Serologic Tests | 2 | 2014 | 137 | 0.110 |
Why?
|
| Encephalitozoon cuniculi | 2 | 2002 | 2 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 1995 | 428 | 0.100 |
Why?
|
| Antigens, Protozoan | 2 | 2005 | 66 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 4320 | 0.100 |
Why?
|
| Global Health | 3 | 2019 | 657 | 0.100 |
Why?
|
| Interleukin-15 | 3 | 2001 | 185 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 1390 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 2045 | 0.100 |
Why?
|
| Campylobacter jejuni | 1 | 2010 | 4 | 0.100 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.100 |
Why?
|
| Biomarkers | 4 | 2016 | 5047 | 0.100 |
Why?
|
| Campylobacter Infections | 1 | 2010 | 36 | 0.100 |
Why?
|
| Time Factors | 7 | 2019 | 12926 | 0.100 |
Why?
|
| Malaria | 1 | 2011 | 92 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 397 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 2927 | 0.090 |
Why?
|
| Cell Line | 2 | 2009 | 5114 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2007 | 1555 | 0.090 |
Why?
|
| Interleukin-4 | 2 | 2001 | 284 | 0.090 |
Why?
|
| Dengue | 1 | 2011 | 109 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2011 | 542 | 0.090 |
Why?
|
| Cattle | 3 | 2008 | 783 | 0.090 |
Why?
|
| Carrier State | 1 | 2010 | 90 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 1375 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Water | 2 | 2006 | 361 | 0.090 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1323 | 0.090 |
Why?
|
| Adhesins, Escherichia coli | 2 | 2020 | 24 | 0.090 |
Why?
|
| Thiazoles | 2 | 2004 | 726 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1763 | 0.090 |
Why?
|
| Genotype | 6 | 2014 | 4109 | 0.090 |
Why?
|
| Immunoglobulin M | 3 | 2014 | 347 | 0.090 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2009 | 5 | 0.090 |
Why?
|
| Rehydration Solutions | 1 | 1989 | 9 | 0.090 |
Why?
|
| Furazolidone | 1 | 1989 | 7 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2013 | 850 | 0.090 |
Why?
|
| Giardiasis | 1 | 1989 | 15 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 127 | 0.090 |
Why?
|
| Diarrhea, Infantile | 1 | 1989 | 43 | 0.080 |
Why?
|
| Escherichia coli Vaccines | 1 | 2008 | 1 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 1994 | 691 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2008 | 2316 | 0.080 |
Why?
|
| Enterococcus faecium | 1 | 2008 | 46 | 0.080 |
Why?
|
| Parasite Egg Count | 4 | 2006 | 33 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 451 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 1995 | 1320 | 0.080 |
Why?
|
| Antibodies, Catalytic | 1 | 2007 | 9 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 1099 | 0.080 |
Why?
|
| Adhesins, Bacterial | 1 | 2008 | 85 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5637 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2007 | 62 | 0.080 |
Why?
|
| Dog Diseases | 1 | 2008 | 73 | 0.080 |
Why?
|
| Virus Replication | 1 | 2011 | 709 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 1989 | 182 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 101 | 0.070 |
Why?
|
| Azithromycin | 1 | 2007 | 78 | 0.070 |
Why?
|
| Monocytes | 1 | 2011 | 788 | 0.070 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 157 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2009 | 314 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 709 | 0.070 |
Why?
|
| Temperature | 1 | 2008 | 506 | 0.070 |
Why?
|
| Child | 7 | 2020 | 29154 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2016 | 16273 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2011 | 297 | 0.070 |
Why?
|
| Probability | 2 | 2007 | 866 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 117 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 1538 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 299 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 1688 | 0.070 |
Why?
|
| Prognosis | 6 | 2020 | 21713 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 14289 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 42 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2006 | 192 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 3 | 1999 | 19 | 0.070 |
Why?
|
| Linear Models | 2 | 2007 | 1085 | 0.070 |
Why?
|
| Phenanthrolines | 3 | 2002 | 9 | 0.060 |
Why?
|
| Coccidiostats | 1 | 2004 | 2 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 1130 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2013 | 994 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 5377 | 0.060 |
Why?
|
| Collagen | 1 | 2008 | 752 | 0.060 |
Why?
|
| Colonic Diseases, Functional | 1 | 2004 | 16 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2013 | 2315 | 0.060 |
Why?
|
| Macrophages | 1 | 2011 | 1304 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 3472 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2011 | 1544 | 0.060 |
Why?
|
| Edetic Acid | 3 | 2002 | 73 | 0.060 |
Why?
|
| Viral Load | 2 | 2010 | 493 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 6550 | 0.060 |
Why?
|
| Gelatinases | 1 | 2004 | 52 | 0.060 |
Why?
|
| Immunologic Techniques | 1 | 2003 | 43 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 703 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 1994 | 2819 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2023 | 58 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 4053 | 0.060 |
Why?
|
| Cross Infection | 1 | 2008 | 544 | 0.060 |
Why?
|
| Substance P | 1 | 2003 | 71 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 2314 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 419 | 0.060 |
Why?
|
| Mice | 5 | 2022 | 34495 | 0.060 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.060 |
Why?
|
| Vittaforma | 1 | 2002 | 1 | 0.060 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2004 | 87 | 0.060 |
Why?
|
| Propionates | 1 | 2022 | 71 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2010 | 1053 | 0.050 |
Why?
|
| Probability Theory | 1 | 2002 | 6 | 0.050 |
Why?
|
| Base Sequence | 3 | 2008 | 4917 | 0.050 |
Why?
|
| Sex Factors | 1 | 2008 | 2139 | 0.050 |
Why?
|
| Encephalitozoon | 1 | 2002 | 1 | 0.050 |
Why?
|
| Leucyl Aminopeptidase | 1 | 2002 | 4 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 189 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 14889 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2002 | 35 | 0.050 |
Why?
|
| Herbal Medicine | 1 | 2001 | 11 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2007 | 6100 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 3639 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 305 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 4233 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2002 | 406 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 285 | 0.050 |
Why?
|
| Encephalitozoonosis | 1 | 2001 | 1 | 0.050 |
Why?
|
| Metagenome | 1 | 2022 | 176 | 0.050 |
Why?
|
| Texas | 3 | 2020 | 6311 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 10035 | 0.050 |
Why?
|
| Gene Library | 1 | 2002 | 294 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2019 | 886 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2005 | 1244 | 0.050 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 25 | 0.050 |
Why?
|
| Caspase 1 | 1 | 2020 | 64 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 6089 | 0.050 |
Why?
|
| Fimbriae, Bacterial | 1 | 2020 | 66 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 336 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2020 | 100 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 997 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 54 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2001 | 553 | 0.050 |
Why?
|
| Iowa | 1 | 1999 | 17 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2013 | 1313 | 0.040 |
Why?
|
| Thioguanine | 1 | 2019 | 68 | 0.040 |
Why?
|
| Biodiversity | 1 | 2020 | 91 | 0.040 |
Why?
|
| Bacteria | 2 | 2013 | 611 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 1213 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2001 | 333 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2001 | 461 | 0.040 |
Why?
|
| Guatemala | 2 | 2010 | 67 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4298 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 634 | 0.040 |
Why?
|
| Gastric Mucosa | 2 | 2019 | 613 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 240 | 0.040 |
Why?
|
| DNA Fingerprinting | 2 | 2010 | 167 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 2 | 2010 | 139 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2002 | 499 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 184 | 0.040 |
Why?
|
| DNA | 1 | 2007 | 2693 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 301 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 430 | 0.040 |
Why?
|
| Treatment Outcome | 7 | 2021 | 32848 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 495 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 460 | 0.040 |
Why?
|
| Genome | 1 | 2022 | 672 | 0.040 |
Why?
|
| Recurrence | 2 | 2019 | 4758 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 7548 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 1999 | 756 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 698 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 338 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 375 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 619 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2001 | 667 | 0.040 |
Why?
|
| Tuberculosis, Miliary | 1 | 1997 | 12 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 241 | 0.040 |
Why?
|
| Spores | 1 | 1996 | 7 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 1293 | 0.040 |
Why?
|
| Telomerase | 1 | 2020 | 525 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2001 | 1021 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 2594 | 0.040 |
Why?
|
| Acute Disease | 2 | 2007 | 2422 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4557 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 670 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 29902 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.040 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.030 |
Why?
|
| Life Style | 1 | 2019 | 612 | 0.030 |
Why?
|
| Leg | 1 | 1997 | 226 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2007 | 111 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 373 | 0.030 |
Why?
|
| Phylogeny | 2 | 2010 | 826 | 0.030 |
Why?
|
| Abscess | 1 | 1997 | 177 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 657 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 2 | 2008 | 128 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 521 | 0.030 |
Why?
|
| Boronic Acids | 1 | 1996 | 362 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1994 | 48 | 0.030 |
Why?
|
| Kinetics | 2 | 2013 | 2049 | 0.030 |
Why?
|
| Mucorales | 1 | 1994 | 31 | 0.030 |
Why?
|
| Streptomycin | 1 | 1993 | 16 | 0.030 |
Why?
|
| DNA Primers | 2 | 2008 | 1399 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2014 | 129 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1879 | 0.030 |
Why?
|
| Infant | 2 | 2004 | 13310 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 1973 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 289 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 52 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 216 | 0.030 |
Why?
|
| Culture Media | 1 | 1993 | 319 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2013 | 164 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.030 |
Why?
|
| Models, Biological | 1 | 2002 | 3254 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1048 | 0.030 |
Why?
|
| Ribavirin | 1 | 2013 | 178 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 218 | 0.030 |
Why?
|
| Water Supply | 2 | 2006 | 24 | 0.030 |
Why?
|
| Liposomes | 1 | 1994 | 684 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 4804 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2002 | 5710 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| Phospholipids | 1 | 2013 | 177 | 0.030 |
Why?
|
| Central America | 1 | 2011 | 29 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2011 | 34 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2014 | 267 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 827 | 0.030 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2011 | 34 | 0.030 |
Why?
|
| Chelating Agents | 2 | 2002 | 127 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 2218 | 0.030 |
Why?
|
| Molecular Weight | 2 | 2002 | 629 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2010 | 2483 | 0.030 |
Why?
|
| Endemic Diseases | 1 | 2011 | 67 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2011 | 62 | 0.020 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2011 | 6 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2011 | 72 | 0.020 |
Why?
|
| Prevalence | 2 | 2010 | 3260 | 0.020 |
Why?
|
| Substrate Specificity | 2 | 2002 | 549 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 4938 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 2003 | 6150 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2738 | 0.020 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2010 | 9 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1997 | 3033 | 0.020 |
Why?
|
| Citrobacter | 1 | 2010 | 22 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2010 | 71 | 0.020 |
Why?
|
| Cities | 1 | 2010 | 49 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 397 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 777 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 140 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 3151 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2010 | 185 | 0.020 |
Why?
|
| India | 1 | 2010 | 301 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2013 | 889 | 0.020 |
Why?
|
| Turkeys | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 14551 | 0.020 |
Why?
|
| Biopsy | 3 | 2001 | 3443 | 0.020 |
Why?
|
| Plasmids | 2 | 2001 | 837 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2008 | 128 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 1037 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 497 | 0.020 |
Why?
|
| Pseudogenes | 1 | 2008 | 81 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2011 | 349 | 0.020 |
Why?
|
| Haptens | 1 | 2007 | 15 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2008 | 239 | 0.020 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2007 | 24 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 141 | 0.020 |
Why?
|
| Chickens | 1 | 2008 | 523 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 671 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2007 | 227 | 0.020 |
Why?
|
| Glucosyltransferases | 1 | 2007 | 54 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2007 | 299 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 437 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 2008 | 222 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 4757 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 1038 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2006 | 105 | 0.020 |
Why?
|
| Dogs | 1 | 2008 | 1155 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2013 | 1230 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2005 | 32 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 7789 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 148 | 0.020 |
Why?
|
| Chemokines | 1 | 2006 | 314 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2001 | 3536 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2005 | 211 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 2004 | 69 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 437 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 1541 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 201 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 2002 | 29 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2020 | 11965 | 0.010 |
Why?
|
| Coumarins | 1 | 2002 | 33 | 0.010 |
Why?
|
| Fluorometry | 1 | 2002 | 34 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 568 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 4314 | 0.010 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 2001 | 38 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 4988 | 0.010 |
Why?
|
| Sesquiterpenes | 1 | 2001 | 68 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2001 | 94 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10331 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 459 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 769 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 869 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 1442 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1999 | 182 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 7551 | 0.010 |
Why?
|
| Parasitology | 1 | 1997 | 9 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 15862 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 3719 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 6295 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4367 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2001 | 4307 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1997 | 426 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 7222 | 0.000 |
Why?
|